apposters.com
Seventure Partners
Edit

Seventure Partners

https://www.seventure.fr
Last activity: 10.06.2026
Active
With over €660m in assets under management as of the end of 2016, Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure Partners has invested in innovative businesses with high growth potential in Digital technologies, especially fintech & insurtech, in France and Germany, and in the Life sciences field across Europe, North America ans Asia. Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage. Seventure is a subsidiary of Natixis Global Asset Management. Natixis is the corporate investment management and financial services arm of Groupe BPCE, the second-largest French bank. For more details: www.seventure.com
Followers
9.92K
News
244
Portfolio
5
Mentions
81
Location: France, Ile-de-France, Paris
Employees: 11-50
Founded date: 1997
Investment Type: Venture Capital
Investment Stage: Series A; Series B; Series C; Series D; Series E; Series F; Series G; Series H

Portfolio 5

DateNameWebsiteTotal RaisedLocation
15.10.2025Tubulistubulis.com$629.54MGermany
30.03.2023Glopalmerchants.glopal.com$26.26MFrance, Il...
29.03.2023Glopalglopal.com$21.78MMetropolit...
05.05.2021Cytoki Pha...cytokipharma.com$45MDenmark, G...
10.11.2014Humedics G...humedics.eu$7.83MGermany, B...

News 244

DateTitleDescription
05.12.2023Eligo Bioscience Raises $30 Million To Write a Novel Chapter for Genetic MedicinesEligo Bioscience, a pioneering gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, has announced a successful...
31.10.2023MaaT Pharma to Present Preclinical Data at SITC on MaaT034, an Artificial Intelligence-Generated Product Aimed at Improving Patients’ Responses to ImmunotherapiesMaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to...
30.10.2023Enterome Selected to The Leukemia & Lymphoma Society’s Therapy Acceleration ProgramEnterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry...
26.10.2023Pharma announces positive outcome following DSMB review reinforcing confidence in phase 3 on-going trial.Maat Pharma announces that the DSMB unanimoulsy recommended that the open-label, single arm pivotal Phase 3 clinical trial evaluating MaaT013 in acute Graft-versus-Host Disease...
26.10.2023MaaT Pharma Announces Positive Outcome Following DSMB Review Reinforcing Confidence in Phase 3 On-Going Trial in Acute Graft-versus-Host Disease with MaaT013MaaT Pharma today announced that the DSMB unanimously recommended that the open-label, single arm pivotal Phase 3 clinical trial evaluating MaaT013 in acute Graft-versus-Host...
09.10.2023CorWave announces the grand opening of its manufacturing facility on the banks of the Seine, next to ParisA French company that develops and manufactures innovative cardiac assist devices, held the grand opening of its new facility on the banks of the Seine in Clichy, next to...
29.08.2023Citryll Announces Appointments of Eduardo Bravo as CEO and Tim Schenk as CBOCitryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Eduardo...
24.08.2023Alliance Promotion Microbiote applauds the new legislation securing stool collection in FranceThe Alliance Promotion Microbiote (APM), a prominent player dedicated to the development, production, and commercialization of therapeutic microbiome-based innovations,...
30.06.2023Enterome announces first patient dosed in a Phase 1/2 trial with third OncoMimics™ immunotherapy, EO4010, in Metastatic Colorectal CancerEnterome today announces that the first patient was dosed in the Phase 1/2 'AUDREY' trial evaluating EO4010, the Company's third OncoMimics™ candidate, for the treatment of...
14.06.2023Enterome’s new OncoMimics™ immunotherapy, EO2463, demonstrates early efficacy and favorable safety in Phase 1/2 trial for indolent non-Hodgkin lymphomaEnterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry...
Show more

Mentions in press and media 81

DateTitleDescription
10.06.2026Physical AI Powerhouse: Neura Robotics Lands $1.4 Billion InvestmentNeura Robotics secured a record $1.4 billion Series C funding. Global tech giants like Amazon, NVIDIA, Qualcomm, and Tether led the investment. This catapults Neura's valuation to $7 billion, achieving unicorn status. The company pioneers c...
10.06.2026Neura Robotics erhält 1,4 MilliardenIm #DealMonitor für den 10. Juni werfen wir einen Blick auf die wichtigsten, spannendsten und interessantesten Investments und Exits des Tages in der DACH-Region. Alle Deals der Vortage gibt es im großen und übersichtlichen #DealMonitor-Arc...
19.05.2026Natixis Investment Managers’ Funds Honored at the 2026 LSEG Lipper Fund Awards WorldwideNatixis Investment Managers (Natixis IM) today announced that several of its affiliate asset management companies, including DNCA Investments, Dorval Asset Management, Mirova*, Ostrum Asset Management, Vega Investment Solutions, and WCM Inv...
31.03.2026Standing Ovation nets $34m, gears up for US launch of casein via precision fermentationFrench startup Standing Ovation has raised a €25 million ($28.5 million) Series B round and secured an additional €5 million ($5.7 million) in non-dilutive funding to scale dairy proteins via precision fermentation. The round was jointly le...
16.10.2025German biotech Tubulis secures record-breaking €308M Series CTubulis, a pioneer in the development of uniquely matched antibody-drug conjugates (ADCs), this week announced the successful closing of a €308 million Series C financing round. This landmark round marks the largest Series C raised by a Eur...
15.10.2025Tubulis Raises €308 Million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline• USD 361 million round represents the largest Series C for a European biotechnology company and the largest financing for a private ADC developer globally • Round led by Venrock Healthcare Capital Partners with participation from other new...
01.10.2025Sunrise Group: $29 Million Raised For Expanding Dreem HealthSunrise Group, known as a leader in sleep health technology, has announced a funding round of $29 million dedicated to expanding Dreem Health, its innovative digital sleep clinic, to ensure its services reach all 50 states in the U.S. This ...
25.09.2025Sunrise Group Raises $29M to Expand Dreem Health and Build the Largest U.S. Sleep ClinicWhat You Should Know: –Sunrise Group, a leader in sleep health technology, today announced a $29 million funding round to expand Dreem Health, its digital sleep clinic, across all 50 states. – The round was led by Eurazeo, with participatio...
23.09.2025+++ mymuesli-Mafia +++ Sentryc +++ Luqom Group +++ Calm/Storm +++Was gibt’s Neues? In unserem #StartupTicker liefern wir eine kompakte Übersicht über die wichtigsten Startup-Nachrichten des Tages (Dienstag, 23. September). #STARTUPLAND SAVE THE DATE: Am 5. November findet unsere zweite STARTUPLAND statt....
03.05.2025Empowering Tomorrow: The Rise of Student-Led Initiatives at Oakridge International SchoolIn the heart of Bengaluru, a revolution is brewing. Oakridge International School is redefining education through student-led initiatives. This isn’t just a school; it’s a launchpad for future leaders. Here, students are not mere recipients...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In